OAM
AKRO

Oxford Asset Management’s Akero Therapeutics AKRO Stock Holding History

Oxford Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,905
Closed -$353K – 249
2019
Q4 		$353K Sell
15,905
-54,994
-78% -$1.14M 0.01% 1381
2019
Q3 		$1.61M Sell
70,899
-42,409
-37% -$987K 0.04% 670
2019
Q2 		$2.17M Buy
+113,308
New +$2.15M 0.05% 607

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Oxford Asset Management's AKRO Position: Q1 2020 in Review

Oxford Asset Management sold out of Akero Therapeutics (AKRO) in Q1 2020, closing a stake of 15,905 shares — an estimated $353K sold.

Oxford Asset Management first reported a position in AKRO in Q2 2019 and held it in 3 quarters. The position peaked at $2.17M in Q2 2019. 67 funds tracked by Wall St. Rank hold AKRO as of Q1 2020.

  • Oxford Asset Management reported no remaining Akero Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 15,905 Akero Therapeutics shares in Q1 2020, an estimated $353K.
  • Oxford Asset Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 3 quarters.
  • Oxford Asset Management's Akero Therapeutics position peaked at $2.17M in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.